Name: Latest research reports of Zydus Lifesciences Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 3
Author: Phillip Capital

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer

949.0500 -20.75 (-2.14%)

NSE Aug 01, 2025 15:31 PM

28.34% Fall from 52W High

Volume: 1.3M

Zydus Lifesciences Ltd.

08 Feb 2016

949.05

-2.14%

Cadila 8Feb2016

Neutral: Zydus Lifesciences Ltd.

Target

Phillip Capital

9 CDH management is optimistic about the quick resolution of Warning Letter on its Moraiyaplant.ItexpectcontinuedUSgrowthmomentumledbynewlaunchesfromits recentlyUSFDAapprovedalternateplantsatBaddiandAhmadabadSEZ....

Deven Choksey released a Buy report for Zydus Lifesciences Ltd. with a price target of 1069.0 on 25 Jul, 2025.